WDGMC
5.4.2022 08:47:12 CEST | Business Wire | Press release
Wits University Donald Gordon Medical Centre announced novel study results indicating for the first time that Ultraviolet (UV) room decontamination technology paired with manual cleaning protocols decreased the transmission of Carbapenem-resistant Enterobacterales (CRE) by 23% in a hospital setting. The study results have been published in the March 2022 issue of The Journal of Hospital Infection.
The team of researchers at Wits Donald Gordon Medical Centre (WDGMC), the first private teaching hospital in South Africa, demonstrated the reduction in CRE transmission following a 26-month study and the sustained use of a UV room decontamination device (UVDI-360 Room Sanitizer, provided by US-based manufacturer UVDI and eHealthGroup Infection Control) as an adjunct to standard cleaning, including the use of bleach and quaternary ammonium disinfectants, across the 210-bed hospital. The intervention included broad UV room decontamination across five high-risk patient units (including critical care, oncology, transplant and gastrointestinal surgery rooms) during a 12-month period following a 12-month baseline and two-month, wash-in period.
“Our team’s study indicated that enhanced environmental hygiene utilizing UV room decontamination technology in the hospital can help prevent the transmission of Carbapenem-resistant Enterobacterales , an especially challenging set of multidrug-resistant organisms,” stated lead investigator Dr. Warren Lowman, Clinical Microbiologist & Infection Prevention and Control Specialist, Wits Donald Gordon Medical Centre.
The UV room decontamination device was implemented in three usage scenarios: terminal cleaning following patient discharge, terminal cleaning following patient transfer and, in a novel treatment, occupied rooms where the patient had an existing MDRO infection and was moved during device use. For each scenario, the UV device was operated with five-minute treatment cycles, the number of which varied per room setting and size.
CRE refers to a broader set of microorganisms that demonstrate resistance to at least one of the Carbapenem antibiotics.1 Recent published surveillance studies in South Africa have indicated a CRE infection crude mortality rate of nearly 40%.2
“This research underlines WDGMC’s steadfast commitment to patient and staff safety through the use of novel infection prevention protocols,” said Dr. Sue Tager, Chief Executive Officer, Wits Donald Gordon Medical Centre. “In the ongoing fight to prevent the transmission of superbugs, both in and beyond Africa, these results provide hope and concrete proof that effective solutions exist.”
About Wits Donald Gordon Medical Centre
Wits Donald Gordon Medical Centre (WDGMC) is the first and only private teaching hospital in South Africa. It was established in 2002 when the University of the Witwatersrand (Wits University) bought the Kenridge Hospital with a founding donation from the Donald Gordon Foundation. The institution was then renamed the Wits Donald Gordon Medical Centre. The 210-bed facility’s main specialties are transplant surgery, oncology (paediatric and adult), gastroenterology (medical and surgical), geriatric medicine, interventional radiology ophthalmology, ear-nose and throat, urology, nephrology, cardiology, women’s health and orthopaedics.
___________
1
https://www.cdc.gov/hai/organisms/cre/technical-info.html
2
Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, Bhola P, Ramjathan P, Swe Swe-Han K, Wadula J, Whitelaw A, Smith M, Mbelle N, Singh-Moodley A; for GERMS-SA. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294. doi: 10.1007/s10096-020-03845-4. Epub 2020 Mar 2. PMID: 32124106.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404006042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom